Njambi Mathenge, MD
Cardiovascular Disease · Lebanon, NHNPI 1285053488
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,321 of the $1,660 with a category attached, or 79.6%. 7 manufacturers reported payments, led by Alcon at 31.3% of the total. Reporting peaked in 2024 at $1,121 and has fallen 98.3% since, to $19 in 2025.
Across 25 payments — averaging $66.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$520
- Teleflex LLC$291
- Spectrawave, Inc$269
- Medtronic$229
- Reflow Medical Inc$199
- Abiomed$136
- plus $16 from 1 others
What the payments were for
- Consulting fees$25015%
- Travel & lodging$895%
- Food & beverage$1,32180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 12 | $520 |
| Teleflex LLC | 2 | $291 |
| Spectrawave, Inc | 2 | $269 |
| Medtronic | 5 | $229 |
| Reflow Medical Inc | 2 | $199 |
| Abiomed | 1 | $136 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GUIDELINER$291
- AcrySof IQ PanOptix$226
- RESOLUTE ONYX$140
- Impella$136
- AcrySof IQ PanOptix UV IOL$136
How this compares
$1,660 in reported general payments places this provider in the 60th percentile of 112 cardiovascular disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 28 | $276 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $185 |
| Amlodipine Besylate | 12 | $104 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lebanon
- Kevin KwakuLebanon$79K
- Michael YoungLebanon$53K
- Merle MyersonLebanon$15K
- Ian GilchristLebanon$13K
- Robert DangeloLebanon$10K
- Rumman SyedLebanon$9K
- Mohammadtokir MujtabaLebanon$8K
- Lauren Gilstrap MilleyLebanon$5K
- Fernando Contreras-ValdesLebanon$5K
- David MinLebanon$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.